Anna Vulpetti

21PUBLICATIONS
55CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)GlycoconjugatesProteins and peptides
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jun 09, 2026
Integrating 19Focused Screening with Make-On-Demand Chemical Spaces for Enhanced Fragment Follow-Up.

|Dec 09, 2025
Fragment-based discovery enables direct targeting of the melanoma oncogene MITF.

Deborah Castelletti, Jürgen Hinrichs, Goran Malojčić

|Aug 19, 2024
Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.

Martin Schröder, Martin Renatus, Xiaoyou Liang

|May 10, 2024
Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches.

Anna Vulpetti, Jean-Michel Rondeau, Marie-Hélène Bellance

|Jan 24, 2024
Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.

Alan Zhang, Katherine Seiss, Laurent Laborde

|Jan 04, 2024
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.

Martin Schröder, Martin Renatus, Xiaoyou Liang

Pageof 4

Frequent Collaborators

3 joint publications

Martin Schröder

3 joint publications

Therese-Marie Stachyra

2 joint publications

Edwige Lorthiois

2 joint publications

Upendra A Argikar